Funding Research
Promoting Innovation
The Epilepsy Foundation New England in its partnership with the Epilepsy Foundation of America will work to lead the fight to accelerate therapies to stop seizures, find cures and save lives.
Epilepsy Foundation New England is aligned with EFA in support of policies that promote research and innovation into new therapies and devices, as well as proposals to lift barriers to getting new treatments to patients faster. Innovation is of particular importance to the nearly one million people living with epilepsy who don’t have their seizures under control and are seeking new treatments and a cure, as well as many Americans living with complex chronic and rare conditions that are not appropriately managed with current treatment options.
To help further research and innovation, the Epilepsy Foundation of America has supported the Advancing Research for Neurological Diseases Act (S. 849), which would create a system to gather data about neurological conditions and diseases. Over the last 48 years EFA and its generous supporters have provided over $56 million dollars in funding for research.
The epilepsy foundation research and innovation program is dedicated to four key goals:
- Accelerating new therapies
- Supporting early careers in research
- Driving innovation
- Eliminating Sudden Unexpected Death in Epilepsy (SUDEP)
You can learn more about three key initiatives for 2017 listed below which aim to accelerate epilepsy research and therapies by visiting the national epilepsy foundation website research and innovation information pages.
EI2 (Epilepsy Innovation Institute) will use patient centered input to drive radical new research.
The SUDEP Institute has partnered with InnoCentive to create a reduction to Practice Challenge to develop a predictive biomarker that will identify people at risk for SUDEP.
The Epilepsy Foundation Research Roundtable in Epilepsy (RRE) works tirelessly to find solutions to regulatory barriers to speed delivery of novel therapies to people with epilepsy. The RRE is supported by 20 members representing large and small pharmaceutical, biotechnology, and device companies.